-
1.发明申请公开(公告)号：US20090117098A1
公开(公告)日：2009-05-07
申请号：US12262841
申请日：2008-10-31
IPC分类号： A61K39/395 , A61P27/06
摘要： The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising a Complement C1q inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma, the composition comprising a pharmaceutically effective amount of a Complement C1q inhibitor.
摘要翻译： 本发明在一个实施方案中涉及治疗青光眼或升高的眼内压的方法，包括施用药学有效量的包含补体C1q抑制剂的组合物。 在另一个实施方案中，本发明涉及用于治疗眼内压升高和青光眼的组合物，该组合物包含药学上有效量的补体C1q抑制剂。
-
公开(公告)号：US20120115870A1
公开(公告)日：2012-05-10
申请号：US13348376
申请日：2012-01-11
申请人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shepard , Mark R. Hellberg , Peter G. Klimko , Abbot F. Clark
发明人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shepard , Mark R. Hellberg , Peter G. Klimko , Abbot F. Clark
IPC分类号： A61K31/5377 , C07D401/14 , A61K31/4439 , A61K31/437 , C07D471/04 , A61P27/02 , A61K31/506 , A61P27/06 , A61K31/519 , C07D417/12 , A61K31/495 , C07D413/12 , C07D413/14 , C12Q1/02 , C07D405/14
CPC分类号： G01N33/5008 , A61K31/357 , A61K31/381 , A61K31/4192 , A61K31/4196 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K45/06 , G01N33/5023 , G01N33/5044 , A61K2300/00
摘要： An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
摘要翻译： 公开了一种可用于治疗青光眼和控制眼内压的眼用药物组合物，其包含有效量的ALK5受体活性的选择性调节剂。 还公开了一种治疗青光眼并控制眼内压的方法，其包括将治疗有效量的包含ALK5受体活性的选择性调节剂的药物组合物施用于患者的受影响的眼睛。
-
公开(公告)号：US20090326044A1
公开(公告)日：2009-12-31
申请号：US12536698
申请日：2009-08-06
IPC分类号： A61K31/7105
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K—2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
4.发明申请RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS 审中-公开RNAi介导的抑制肿瘤坏死因子ALPHA相关病症公开(公告)号：US20100166676A1
公开(公告)日：2010-07-01
申请号：US12700188
申请日：2010-02-04
IPC分类号： A61K9/12 , A61K31/7088 , A61K31/7125
CPC分类号： C12N15/1138 , A61K31/7088 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/346 , C12N2310/351 , C12N2320/30
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这样的TNFα靶标可用于治疗患有TNFα相关病症或具有发展TNFα相关病症如眼病干眼症，过敏性结膜炎或眼部炎症或诸如皮炎，鼻炎的患者的患者 ，或哮喘。
-
公开(公告)号：US07592324B2
公开(公告)日：2009-09-22
申请号：US11345361
申请日：2006-02-01
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者的眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
公开(公告)号：US20110160210A1
公开(公告)日：2011-06-30
申请号：US13042848
申请日：2011-03-08
申请人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shapard , Mark R. Hellberg , Abbot F. Clark , Peter G. Klimko
发明人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shapard , Mark R. Hellberg , Abbot F. Clark , Peter G. Klimko
IPC分类号： A61K31/5377 , A61P27/06 , C07D405/14 , A61K31/4439 , C12Q1/02 , C07D401/14 , A61K31/4709 , C07D487/04 , C07D471/04 , A61K31/4375 , A61K31/506 , A61K31/437 , A61K31/519 , A61K31/498 , C07D413/14
CPC分类号： G01N33/5008 , A61K31/357 , A61K31/381 , A61K31/4192 , A61K31/4196 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K45/06 , G01N33/5023 , G01N33/5044 , A61K2300/00
摘要： An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
摘要翻译： 公开了一种可用于治疗青光眼和控制眼内压的眼用药物组合物，其包含有效量的ALK5受体活性的选择性调节剂。 还公开了一种治疗青光眼并控制眼内压的方法，其包括将治疗有效量的包含ALK5受体活性的选择性调节剂的药物组合物施用于患者的受影响的眼睛。
-
公开(公告)号：US07807363B2
公开(公告)日：2010-10-05
申请号：US11680416
申请日：2007-02-28
CPC分类号： G01N33/6893 , A61K31/21 , A61K31/4196 , A61K31/56 , C12Q1/26 , C12Q1/6851 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N2500/00 , G01N2800/168
摘要： The present invention concerns a method for diagnosing or monitoring elevated intraocular pressure or glaucoma in a patient comprising providing a biological sample from the patient and measuring the expression level of a superoxide dismutase-2 (SOD-2) gene in the biological sample. The present invention also concerns methods for treating glaucoma or elevated intraocular pressure in a patient comprising administering to a patient an effective amount of an agent that modulates SOD-2 expression or SOD-2 activity.
摘要翻译： 本发明涉及用于诊断或监测患者中升高的眼内压或青光眼的方法，包括从患者提供生物样品并测量生物样品中超氧化物歧化酶-2（SOD-2）基因的表达水平。 本发明还涉及治疗患者青光眼或升高的眼内压的方法，包括向患者施用有效量的调节SOD-2表达或SOD-2活性的药剂。
-
8.发明授权RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis 有权RNAi相关抑制TNFα信号通路治疗眼血管生成公开(公告)号：US08754202B2
公开(公告)日：2014-06-17
申请号：US13169549
申请日：2011-06-27
IPC分类号： C07H21/04
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症如眼血管生成，视网膜缺血和糖尿病性视网膜病变的风险的患者。
-
9.发明申请RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA 审中-公开用于治疗乳腺癌的TNFα信号通路的RNAi相关性抑制公开(公告)号：US20110190376A1
公开(公告)日：2011-08-04
申请号：US13031358
申请日：2011-02-21
IPC分类号： A61K31/7105 , A61P27/02
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这样的TNFα靶标可用于治疗患有或有发生黄斑水肿风险的患者。
-
10.发明申请RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS 审中-公开用于治疗与眼压相关的病症的阿维菌素4的RNAi介导的抑制公开(公告)号：US20080214486A1
公开(公告)日：2008-09-04
申请号：US11946335
申请日：2007-11-28
CPC分类号： C12N15/1138 , A61K48/00 , C12N2310/14
摘要： RNA interference is provided for inhibition of aquaporin 4 (AQP4) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
摘要翻译： 提供RNA干扰抑制水通道蛋白4（AQP4）在眼内压相关病症中的应用，包括眼高压和青光眼如正常青光眼和开角型青光眼。
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.027 秒)
